PLAY PODCASTS
Pure Global: Singapore's AI MedTech Leap—Navigating Hidden HSA Compliance Traps.

Pure Global: Singapore's AI MedTech Leap—Navigating Hidden HSA Compliance Traps.

ASEAN MedTech Insights · Ran Chen

March 14, 20261m 47s

Audio is streamed directly from the publisher (episodes.captivate.fm) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.

Show Notes

Last week, Singapore's Health Sciences Authority (HSA) launched a new, stringent regulatory framework for AI-enabled medical devices, setting a new benchmark for market access in the ASEAN region. This episode unpacks the critical details of these changes, focusing on the new requirements for algorithmic transparency, data validation, and lifecycle management that are creating immediate challenges for MedTech innovators. We explore the real-world impact through the case of a diagnostic imaging startup. Their market-approved AI software now faces significant hurdles in Singapore, as the new guidelines question the validity of their non-local training data and demand a more rigorous plan for post-market monitoring of algorithmic performance. This case highlights the critical pain point for companies: a previously straightforward market entry plan is now complicated, costly, and uncertain. Key Questions from This Episode: - How does the HSA now define the critical difference between a "locked" and an "adaptive" AI algorithm, and what does it mean for your submission. - What are the three biggest data validation mistakes to avoid when proving your model's efficacy for the local population. - Why is your current cybersecurity protocol likely insufficient for the new AI-specific threat models. - What new post-market surveillance processes are now mandatory to detect "algorithmic drift". - How can you design a change control plan that meets the HSA's rigorous standards for model updates. - Are you prepared for the new labeling requirements to ensure clinicians fully understand your device's AI-driven outputs and limitations. Navigating complex regulatory shifts like this is critical for market success. Pure Global offers end-to-end regulatory consulting solutions for MedTech and IVD companies, combining local expertise with advanced AI and data tools to streamline global market access. From developing a robust regulatory strategy and compiling technical dossiers to acting as your local representative, we clear the path for your innovation. Contact us at [email protected] or visit us at https://pureglobal.com/ to learn how we can secure your entry into the Singaporean market and beyond.